Bispecific antibody therapy

预约门诊
打印

科室与专家门诊

妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一，在亚利桑那州、佛罗里达州和明尼苏达州都设有院区。我们的工作人员涉及数十种专业，通过齐心协力确保高品质治疗与成功康复。

有相关专长的科室

行此手术的医生

编辑搜索过滤条件
close

缩小搜索范围

  1. 查找姓氏以该字母开头的医生 A
  2. 查找姓氏以该字母开头的医生 B
  3. 查找姓氏以该字母开头的医生 C
  4. 未找到姓氏以该字母开头的医生 D
  5. 未找到姓氏以该字母开头的医生 E
  6. 未找到姓氏以该字母开头的医生 F
  7. 未找到姓氏以该字母开头的医生 G
  8. 未找到姓氏以该字母开头的医生 H
  9. 未找到姓氏以该字母开头的医生 I
  10. 未找到姓氏以该字母开头的医生 J
  11. 查找姓氏以该字母开头的医生 K
  12. 未找到姓氏以该字母开头的医生 L
  13. 未找到姓氏以该字母开头的医生 M
  14. 未找到姓氏以该字母开头的医生 N
  15. 未找到姓氏以该字母开头的医生 O
  16. 未找到姓氏以该字母开头的医生 P
  17. 未找到姓氏以该字母开头的医生 Q
  18. 未找到姓氏以该字母开头的医生 R
  19. 查找姓氏以该字母开头的医生 S
  20. 未找到姓氏以该字母开头的医生 T
  21. 未找到姓氏以该字母开头的医生 U
  22. 查找姓氏以该字母开头的医生 V
  23. 未找到姓氏以该字母开头的医生 W
  24. 未找到姓氏以该字母开头的医生 X
  25. 未找到姓氏以该字母开头的医生 Y
  26. 查找姓氏以该字母开头的医生 Z
重置所有过滤器

显示$起始范围 - $结束范围/源自可用$可用医生

  1. Stephen M. Ansell, M.D., Ph.D.

    Stephen M. Ansell, M.D., Ph.D.

    1. Internist
    2. Oncologist
    3. Hematologist
    1. Rochester, MN
    擅长领域：

    CAR-T cell therapy, Bispecific antibody therapy, B-cell lymphoma, Non-Hodgkin lymphoma, Burkitt lymphoma, Follicular ly...mphoma, Hodgkin lymphoma

  2. Tanios S. Bekaii-Saab, M.D.

    Tanios S. Bekaii-Saab, M.D.

    1. Oncologist
    1. Phoenix, AZ
    擅长领域：

    Chemotherapy for colon cancer, Bispecific antibody therapy, Cholangiocarcinoma, Colon cancer, Pancreatic cancer, Liver ...cancer, Esophageal cancer, Anal cancer, Stomach cancer, Rectal cancer, Gallbladder cancer, Carcinoma of unknown primary, Neuroendocrine tumor, Gastrointestinal stromal tumor, Small bowel cancer

  3. Joselle M. Cook, M.B.B.S.

    Joselle M. Cook, M.B.B.S.

    1. Internist
    2. Oncologist
    3. Hematologist
    1. Rochester, MN
    擅长领域：

    Bispecific antibody therapy, Multiple myeloma

  4. Prashant Kapoor, M.D.

    Prashant Kapoor, M.D.

    1. Oncologist
    2. Hematologist
    1. Rochester, MN
    擅长领域：

    Bone marrow transplant, CAR-T cell therapy, Bispecific antibody therapy, Multiple myeloma, Amyloidosis, Waldenstrom mac...roglobulinemia

  5. Shaji Kumar, M.D.

    Shaji Kumar, M.D.

    1. Internist
    2. Hematologist
    1. Rochester, MN
    擅长领域：

    Bone marrow transplant, CAR-T cell therapy, Bispecific antibody therapy, Multiple myeloma, Amyloidosis

  6. Jason S. Starr, D.O.

    Jason S. Starr, D.O.

    1. Hematologist / Oncologist
    1. Jacksonville, FL
    擅长领域：

    Chemotherapy for colon cancer, Bispecific antibody therapy, Colon cancer, Pancreatic cancer, Liver cancer, Esophageal c...ancer, Stomach cancer, Pancreatic neuroendocrine tumor, Neuroendocrine tumor

  7. J.C. C. Villasboas Bisneto, M.D.

    J.C. C. Villasboas Bisneto, M.D.

    1. Internist
    2. Oncologist
    3. Hematologist
    1. Rochester, MN
    擅长领域：

    Bone marrow transplant, CAR-T cell therapy, Bispecific antibody therapy, B-cell lymphoma, Lymphoma, Follicular lymphoma

  8. Mojun Zhu, M.D.

    Mojun Zhu, M.D.

    1. Oncologist
    1. Phoenix, AZ
    擅长领域：

    Bispecific antibody therapy, Cholangiocarcinoma, Colon cancer, Pancreatic cancer, Hepatocellular carcinoma, Esophageal ...cancer, Anal cancer, Stomach cancer, Rectal cancer, Neuroendocrine tumor, Small bowel cancer

研究

Mayo Clinic doctors and scientists in the David F. and Margaret T. Grohne Cancer Immunology and Immunotherapeutics Research Program are pursuing cutting-edge research to better understand the interaction between the immune system and cancer cells.

Mayo Clinic doctors are actively conducting clinical trials to develop new ways of using bispecific antibodies to treat cancers. This includes combining bispecific antibodies with other powerful therapies and replacing traditional therapies with newer bispecific antibody-based therapies.

Cancer research is conducted in coordination with Mayo Clinic Comprehensive Cancer Center. Mayo Clinic Comprehensive Cancer Center receives funding from the National Cancer Institute and is designated as a comprehensive cancer center. This designation recognizes the institution's scientific excellence and multidisciplinary resources focused on cancer prevention, diagnosis and treatment.

Publications

See a list of publications about bispecific antibody therapy by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine.

Research Profiles

来自妙佑医疗国际员工

在 Mayo Clinic 治疗

申请预约
关于在 Mayo Clinic 治疗
Jan. 24, 2026
打印
  1. Klein C, et al. The present and future of bispecific antibodies for cancer therapy. Nature Reviews Drug Discovery. 2024; doi:10.1038/s41573-024-00896-6.
  2. Manis JP. Overview of therapeutic monoclonal antibodies. https://www.uptodate.com/contents/search. Accessed Sept. 30, 2025.
  3. Guidi L, et al. Bispecific antibodies in hematologic and solid tumors: Current landscape and therapeutic advances. American Society of Clinical Oncology Educational Book. 2025; doi:10.1200/EDBK-25-473148.
  4. Gu Y, et al. Clinical progresses and challenges of bispecific antibodies for the treatment of solid tumors. Molecular Diagnosis & Therapy. 2024; doi:10.1007/s40291-024-00734-w.
  5. Verma V, et al. Bispecific antibodies in clinical practice: Understanding recent advances and current place in cancer treatment landscape. Clinical and Experimental Medicine. 2025; doi:10.1007/s10238-024-01520-y.
  6. Jain MD, et al. Easy as ABC: Managing toxicities of antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies. ASCO Educational Book. 2025; doi:10.1200/EDBK-25-473916.
  7. Tan CR, et al. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): An International Myeloma Working Group study. Blood Cancer Journal. 2025; doi:10.1038/s41408-025-01259-z.
  8. Choi SM, et al. Mechanism of action and pharmacokinetics of approved bispecific antibodies. Biomolecules & Therapeutics. 2024; doi:10.4062/biomolther.2024.146.
  9. Medical review (expert opinion). Mayo Clinic. Sept. 30, 2025.
  10. Tecvayli (prescribing information). Janssen Biotech; 2022 https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TECVAYLI-pi.pdf. Accessed Sept. 29, 2025.
  11. Imdelltra (prescribing information). Amgen; 2024. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Imdelltra/imdelltra_fpi.pdf. Accessed Oct. 1, 2025.
  12. Raje N, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel. Blood Cancer Journal. 2023; doi:10.1038/s41408-023-00879-7.
  13. Britto J, et al. Bispecific antibody toxicities. CMAJ. 2025; doi:10.1503/cmaj.241384.
  14. Morris EC, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology. 2022; doi:10.1038/s41577-021-00547-6.
  15. Derman B, et al. Real-world evidence evaluating teclistamab in patients with relapsed/refractory multiple myeloma: A systematic literature review. Cancers. 2025; doi:10.3390/cancers17071235.
  16. Health Education & Content Services. Staying connected with remote patient monitoring. Mayo Clinic; 2022.
  17. Altered immunocompetence. Centers for Disease Control and Prevention. https://www.cdc.gov/vaccines/hcp/imz-best-practices/altered-immunocompetence.html. Accessed Nov. 14, 2025.
  18. Rybrevant (prescribing information). Janssen Biotech; 2021. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  19. Blincyto (prescribing information). Amgen; 2014. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  20. Elrexfio (prescribing information). Pfizer; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  21. Hemlibra (prescribing information). Genentech; 2017. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  22. Epkinly (prescribing information). Genmab US; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  23. Vabysmo (prescribing information). Genentech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  24. Lunsumio (prescribing information). Genentech; 2022. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  25. Kimmtrak (prescribing information). Immunocore; 2022. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  26. Haydu E, et al. The rules of T-cell engagement: Current state of CAR T cells and bispecific antibodies in B-cell lymphomas. Blood Advances. 2024; doi.org/10.1182/bloodadvances.2021004535.
  27. Columvi (prescribing information). Genentech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 20, 2025.
  28. Talvey (prescribing information). Janssen Biotech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 26, 2025.

相关

Bispecific antibody therapy